IRVING, Texas---- Vizient, Inc. announces it will participate in today’s Food and Drug Administration /Federal Trade Commission Workshop on a Competitive Marketplace for Biosimilars in Silver Spring, Maryland. The workshop will be held from 9 a.m. to 5 p.m. at the FDA’s White Oak Campus.
The collaborative effort between the two federal agencies aims to encourage appropriate adoption of biosimilar medications and discourage false or misleading statements about these medications as well as deter anticompetitive behaviors in the biologic medication marketplace.
Steven Lucio, PharmD, BCPS, vice president of pharmacy solutions for Vizient, will speak during the public comments portion of the event. Lucio has written extensively on biosimilars, including authoring “Biosimilars and Biologics: Implementation and Monitoring in a Healthcare Setting” published in 2018, and has been quoted in numerous publications about the benefits they bring to health care.
Lucio’s comments today will focus on insights to help advance competition and transparency as related to the regulatory approval process, including eliminating comparative effectiveness studies where clinically justified and increasing access to FDA approval documents for the education of pharmacists and physicians. His comments will also address challenges associated with variable payer coverage and reimbursement decisions.
“We appreciate this collaborative effort by the FDA and FTC to increase awareness and education of biosimilar medications in the marketplace,” said Lucio. “The advancement of biosimilars in health care will create more competition, lower pharmaceutical expenditures for health care providers and, ultimately, lower costs for patients. We commend this effort.”
Vizient is the largest member-driven performance improvement company in the country. Its diverse membership and customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and nonacute health care providers.
About Vizient, Inc.
Vizient, Inc. provides solutions and services that improve the delivery of high-value care by aligning cost, quality and market performance for more than 50% of the nation’s acute care providers, which includes 95% of the nation’s academic medical centers, and more than 20% of ambulatory providers. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $100 billion in annual purchasing volume, to improve patient outcomes and lower costs. Vizient has earned a World’s Most Ethical Company designation from the Ethisphere Institute every year since its inception. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200309005162/en/
Source: Vizient, Inc.
View this news release online at:
德克萨斯州 IRVING ---- Viziant 公司宣布将参加今天在马里兰州银泉市举行的食品药品监督管理局（Food and Drug Administration）/联邦贸易委员会生物类似物竞争市场讲习班。研讨会将于上午9时至下午5时在 FDA 的白橡校园举行。
SteveLucio , PharmD , BCPS , Viziant 药房解决方案副总裁,将在活动的公众评论部分发表讲话。Lucio 已广泛撰写了关于生物仿制药的文章，包括撰写2018年出版的《生物仿制药和生物逻辑：在医疗保健环境中的实施和监测》一书，并在许多出版物中被引用，介绍了它们给医疗保健带来的好处。
卢西奥今天的评论将集中于有助于提高与监管审批程序相关的竞争和透明度的见解，包括取消临床上合理的比较有效性研究，并增加获得 FDA 批准文件的机会，以教育药剂师和医生。他的评论还将处理与可变支付者覆盖范围和偿还决定相关的挑战。
“我们赞赏 FDA 和 FTC 为提高市场对生物生物仿制药药的认识和教育所做的合作努力，” Lucio 说。“生物仿制药类似物在医疗保健方面的进展将创造更多的竞争，降低医疗保健提供者的药品开支，最终降低病人的费用。我们赞扬这项努力。”
关于 Viziant 公司。
Vizient , Inc .为全国50%以上的急性护理提供者（包括全国95%的学术医疗中心和20%以上的门诊提供者）提供改善高价值医疗服务的解决方案和服务。Viziant 提供专业知识、分析和咨询服务，以及每年超过1000亿美元的采购金额的合同组合，以改善患者结果和降低成本。Viziant 自成立以来每年都从 Ethisphere Institute 获得世界上最具道德的公司称号。Viziant 总部位于德克萨斯州的欧文，在美国各地设有办事处。详情请访问 www.vizietinc.com 。
查看 businesswire 上的源代码。网站： https://www.businesswire.com/news/home/202009005162/en/
心绞痛。bolyver @ vizientina.com
资料来源： Viziant 公司。